Halozyme (HALO) announced the approval of Roche’s (RHHBY) Tecentriq SC, using Halozyme’s Enhanze drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency, or MHRA, in Great Britain. Tecentriq subcutaneous SC is co-formulated with Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenous, or IV, infusion. Tecentriq SC will be available to patients in Great Britain for certain types of lung, bladder, breast, and liver cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme price target raised to $48 from $46 at Piper Sandler
- Halozyme price target lowered to $60 from $61 at H.C. Wainwright
- Halozyme raises FY23 non-GAAP EPS view to $2.65-$2.75 from $2.50-$2.65
- Halozyme reports Q2 non-GAAP EPS 74c, consensus 63c
- HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
